No Data
No Data
No Data
No Data
No Data
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
TipRanksApr 27 20:10
Vistagen Announces Positive Results From Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.
BusinesswireApr 25 20:30
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
BusinesswireApr 9 20:30
30 Countries With the Lowest Depression Rates
Yahoo FinanceMar 26 18:24
This Overlooked Corner of Women's Health Could Be a $350 Billion Market Opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
CNBCMar 16 02:33
Vistagen to Present at Stifel 2024 Virtual CNS Days
Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management
BusinesswireMar 11 20:30
No Data
No Data